Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome

Human Pathology

Volumn 46, Issue 9, 2015, Pages 1267-1274

  Jang, Min Hye ^a,b   Kim, Hyun Jeong ^a   Kim, Eun Joo ^a   Chung, Yul Ri ^b   Park, So Yeon ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

CD146; Epithelial mesenchymal transition; Metaplastic carcinoma; Triple negative breast cancer; ZEB1

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; BIOLOGICAL MARKER; CD146 ANTIGEN; CD24 ANTIGEN; HERMES ANTIGEN; NERVE CELL ADHESION MOLECULE; OSTEONECTIN; SMOOTH MUSCLE ACTIN; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VIMENTIN; HOMEODOMAIN PROTEIN; MCAM PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER; ZEB1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHENOTYPE; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; CANCER STEM CELL; CHEMISTRY; FEMALE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TIME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD146; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; TIME FACTORS; TRANSCRIPTION FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84940462949     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.05.010     Document Type: Article

References (35)

1. K.R. Bauer, M. Brown, R.D. Cress, C.A. Parise, and V. Caggiano Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry Cancer 109 2007 1721 1728
2. O. Metzger-Filho, A. Tutt, E. de Azambuja, and et al. Dissecting the heterogeneity of triple-negative breast cancer J Clin Oncol 30 2012 1879 1887
3. S. Irshad, P. Ellis, and A. Tutt Molecular heterogeneity of triple-negative breast cancer and its clinical implications Curr Opin Oncol 23 2011 566 577
4. Y. Sasaki, and H. Tsuda Clinicopathological characteristics of triple-negative breast cancers Breast Cancer 16 2009 254 259
5. L.A. Carey, E.C. Dees, L. Sawyer, and et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2007 2329 2334
6. B.D. Lehmann, J.A. Bauer, X. Chen, and et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 121 2011 2750 2767
7. J.P. Thiery, H. Acloque, R.Y. Huang, and M.A. Nieto Epithelial-mesenchymal transitions in development and disease Cell 139 2009 871 890
8. R. Kalluri, and R.A. Weinberg The basics of epithelial-mesenchymal transition J Clin Invest 119 2009 1420 1428
9. C.D. May, N. Sphyris, K.W. Evans, S.J. Werden, W. Guo, and S.A. Mani Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression Breast Cancer Res 13 2011 202
10. T. Blick, H. Hugo, E. Widodo, and et al. Epithelial-mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer J Mammary Gland Biol Neoplasia 15 2010 235 252
11. S.A. Mani, W. Guo, M.J. Liao, and et al. The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 133 2008 704 715
12. T.E. Anwar, and C.G. Kleer Tissue-based identification of stem cells and epithelial-to-mesenchymal transition in breast cancer Hum Pathol 44 2013 1457 1464
13. D. Sarrio, S.M. Rodriguez-Pinilla, D. Hardisson, A. Cano, G. Moreno-Bueno, and J. Palacios Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype Cancer Res 68 2008 989 997
14. H. Jeong, Y.J. Ryu, J. An, Y. Lee, and A. Kim Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype Histopathology 60 2012 E87 E95
15. Y. Choi, H.J. Lee, M.H. Jang, and et al. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer Hum Pathol 44 2013 2581 2589
16. M.E. Hammond, D.F. Hayes, M. Dowsett, and et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2010 2784 2795
17. A.C. Wolff, M.E. Hammond, J.N. Schwartz, and et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
18. H.S. Park, M.H. Jang, E.J. Kim, and et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer Mod Pathol 27 2014 1212 1222
19. H. Masuda, K.A. Baggerly, Y. Wang, and et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes Clin Cancer Res 19 2013 5533 5540
20. H.C. Lien, Y.H. Hsiao, Y.S. Lin, and et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition Oncogene 26 2007 7859 7871
21. B. Weigelt, B. Kreike, and J.S. Reis-Filho Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis Breast Cancer Res Treat 117 2009 273 280
22. N. Yamashita, E. Tokunaga, H. Kitao, and et al. Vimentin as a poor prognostic factor for triple-negative breast cancer J Cancer Res Clin Oncol 139 2013 739 746
23. S. Kashiwagi, M. Yashiro, T. Takashima, and et al. Significance of E-cadherin expression in triple-negative breast cancer Br J Cancer 103 2010 249 255
24. D. Tang, S. Xu, Q. Zhang, and W. Zhao The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer Med Oncol 29 2012 526 533
25. G. Zabouo, A.M. Imbert, J. Jacquemier, and et al. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines Breast Cancer Res 11 2009 R1
26. G.F. Zeng, S.X. Cai, and G.J. Wu Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells BMC Cancer 11 2011 113
27. S. Garcia, J.P. Dales, E. Charafe-Jauffret, and et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype Hum Pathol 38 2007 830 841
28. Q. Zeng, W. Li, D. Lu, and et al. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer Proc Natl Acad Sci U S A 109 2012 1127 1132
29. S. Spaderna, O. Schmalhofer, M. Wahlbuhl, and et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer Cancer Res 68 2008 537 544
30. J. Comijn, G. Berx, P. Vermassen, and et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion Mol Cell 7 2001 1267 1278
31. A. Eger, K. Aigner, S. Sonderegger, and et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells Oncogene 24 2005 2375 2385
32. Y. Soini, H. Tuhkanen, R. Sironen, and et al. Transcription factors zeb1, twist and snai1 in breast carcinoma BMC Cancer 11 2011 73
33. P. Karihtala, P. Auvinen, S. Kauppila, K.M. Haapasaari, A. Jukkola-Vuorinen, and Y. Soini Vimentin, zeb1 and sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype Breast Cancer Res Treat 138 2013 81 90
34. M. Singh, N.S. Spoelstra, A. Jean, and et al. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease Mod Pathol 21 2008 912 923
35. N.S. Spoelstra, N.G. Manning, Y. Higashi, and et al. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers Cancer Res 66 2006 3893 3902